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Purpose: Tracheal stenosis can be a life-threatening problem in children. 
Long-segment tracheal stenosis and recurrent tracheal stenosis are especially 
problematic. Tracheal homograft reconstruction represents a novel therapeu- 
tic modality for these patients. Methods: Cadaveric trachea is harvested, fixed 
in formalin, washed in thimerosal (Methiolate), and stored in acetone. The 
stenosed tracheal segment is opened to widely patent segments proximally and 
distally. The anterior cartilage is excised and the posterior trachealis muscle or 
tracheal wall remains. A temporary silicone rubber intraluminal stent is 
placed and absorbable sutures secure the homograft. Regular postoperative 
bronchoscopic treatment clears granulation tissue. The stent is removed 
endoscopically after epithelialization ver the homograft. Twenty-four children 
with severe tracheal stenosis (age 5 months to 18 years, mean -+ standard error 
of the mean = 8.18 + 1.21 years) underwent tracheal homograft reconstruc- 
tion. All but one had had previous unsuccessful reconstructive attempts. Ten 
lesions were congenital, nine were posttraumatic, and five were due to 
prolonged intubation. Results: Follow-up ranged from 5 months to 10 years 
(3.79 -+ 0.70 years). Twenty patients urvive (20/24 = 83%), 16 without any 
airway problems. Four patients are still undergoing treatment. One patient 
requiring emergency extracorporeal membrane oxygenator support before the 
operation died 10 days after tracheal homograft reconstruction. Another 
patient with severe preoperative mediastinal sepsis died 3.5 months after 
tracheal homograft reconstruction. Two patients with functional airways died 
late of unrelated problems. Conclusions: Tracheal homograft reconstruction 
demonstrates ncouraging short-term to medium-term results for children 
with severe recurrent racheal stenosis. Postoperative bronchoscopic and 
histologic studies provide evidence of epithelialization a d support he expec- 
tation of good long-term results. (J Thorac Cardiovasc Surg 1996;112:1549-60) 
T racheal stenosis can be a life-threatening prob- lem in children. Certain types of tracheal stenosis 
are especially problematic 1' 2 including both long- 
segment congenital tracheal stenosis and recurrent 
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tracheal stenosis. Long-segment congenital tracheal 
stenosis, involving more than 50% of the trachea, is 
often associated with pulmonary vascular sling 
(25%), intracardiac lesions (20%), and right-sided 
aortic arch. 3'4 Long-segment congenital tracheal 
stenosis often involves complete cartilaginous rings 
over the length of the stenosis. 5 Although resection 
and primary end-to-end anastomosis has been the 
initial treatment of choice for most shorter stenoses, 
this treatment is considered ifficult in long-segment 
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Table I. Patient data 
Prior tracheal Age at Current status Length of 
Patient operation THR Surgical follow-up 
No. Initial diagnosis (yes or no) (yr) approach Alive or dead Airway problems (yr) 
1 Multiple trauma Yes 16.61 Cervical Alive No 9.96 
2 Multiple trauma Yes 17.53 Cervical Alive No 7.47 
3 Multiple trauma Yes 18.31 Cervical Alive No 6.76 
4 Multiple trauma Yes 9.52 Cervical Alive No 9.11 
5 Multiple trauma Yes 6.36 Cervical Alive No 5.64 
6 Multiple trauma Yes 6.73 Cervical Alive No 8.16 
7 Multiple trauma Yes 11.53 Cervical Dead N/A N/A 
8 Multiple trauma Yes 3.97 Cervical Alive No 5.03 
9 LSCTS Yes 4.13 Cervical Alive No 4.76 
10 LSCTS Yes 5.63 Cervical Alive No 1.37 
11 Neurologic disorder Yes 11.35 Cervical Alive No 4.41 
12 Pneumonia Yes 9.65 Cervical Alive No 0.39 
13 Status epilepticus Yes 13.35 Cervical Alive No 2.06 
14 Toxic shock Yes 15.50 Cervical Alive MNF 2.00 
15 Pneumonia Yes 17.97 Cervical Alive MNF 1.59 
16 LSCTS Yes 4.96 Cervical Alive No 1.38 
17 Multiple trauma Yes 5.58 Cervical Alive MNF 0.43 
18 LSCTS Yes 1.59 Cervical Alive No 0.44 
19 LSCTS/PVS Yes 5.10 Sternotomy Dead N/A N/A 
20 LSCTS/PVS Yes 8.24 Sternotomy Alive No 1.88 
21 LSCTS/PVS/VSD Yes 1.46 Sternotomy Alive No 1.71 
22 LSCTS/PVS Yes 0.44 Sternotomy Dead N/A N/A 
23 LSCTS No 0.42 Sternotomy Alive MNF 1.20 
24 LSCTS/PVS Yes 0.46 Sternotomy Dead N/A N/A 
No. 24 20 
Mean 8.18 3.79 
Median 6.55 2.03 
Range 0.42-18.31 0.39-9.96 
STDEV 5.91 3.12 
SEM 1.21 0.70 
LSCTS, Long-segment congenital tracheal stenosis; MNF, management not finished; N/A, not applicable; PVS, pulmonary vascular sling; SEM, standard error 
of the mean; STDEV, standard deviation; THR, tracheal homograft reconstruction; VSD, ventricular septal defect. 
congenital tracheal stenosis. 6 Numerous other treat- 
ment options have been proposed for long-segment 
congenital tracheal stenosis, 5-16 but none have been 
uniformly successful. 
Recurrent  tracheal stenosis is a part icular ly 
chal lenging surgical prob lem in chi ldren. Recur-  
rent scarring, impaired healing, infection, devas- 
cularization, and life-threatening anastomotic disrup- 
tions all are known complications of cases of recurrent 
tracheal stenosis. 17 Recurrent tracheal stenosis is sim- 
ilar to long-segment congenital tracheal stenosis in 
that a variety of both nonsurgical nd surgical options 
may be used, each with different success rates in 
different subgroups of pat ientsS'  18 
Tracheal  homograft  reconstruct ion (THR)  with 
cadaveric human tracheal homograft  represents a 
novel therapeut ic  opt ion for chi ldren with either 
long-segment congenital  tracheal stenosis, recur- 
rent tracheal stenosis, or both. THR was initially 
introduced by one of us (C.H.) in 1979 as a 
t reatment  for tracheal stenosis in adults. 19-21 We 
described recently the appl icat ion of THR to 
more distal tracheal and proximal bronchia l  le- 
sions in chi ldren through the use of median 
sternotomy and card iopulmonary bypass. 22 We 
now report our total pediatr ic experience with 24 
chi ldren undergo ing THR as t reatment  for long- 
segment congenital  tracheal stenosis, recurrent  
tracheal stenosis, or both. 
Patients and methods 
Patients. Twenty-four children (aged 5 months to 18 
years, mean _+ standard error of the mean [SEM] = 
8.18 _+ 1.21 years) underwent THR. All had severe 
life-threatening tracheal stenosis. Twenty-three of these 
children had undergone previous unsuccessful surgical 
reconstructive attempts. The remaining patient was re- 
ferred to us at 2 months of age with tracheal stenosis and 
had a cardiorespiratory arrest after unsuccessful balloon 
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Fig. 1. The actual homograft is shown as it appears on arrival from the homograft bank. Also shown are 
two Dumon stents. 
dilatation ecessitating the institution of emergency extra- 
corporeal membrane oxygenation (ECMO). 
Ten lesions were congenital (long-segment congenital 
tracheal stenosis), nine were posttraumatic, and five were 
due to prolonged intubation. Eighteen patients (75%) 
required neck incisions only. Six children (25%) required 
sternotomy. Three patients (12.5%) without functional 
airways required stabilization with preoperative ECMO. 
Further details about hese 24 children are presented in 
Table I. 
Homograft procurement and preparation. Cadaveric 
tracheas are moved within 24 hours of death either at 
multiorgan retrieval or at autopsy from donors aged 16 to 
60 years. Contraindications are donors who are positive 
for hepatitis B or C or human immunodeficiency virus, 
donors who have died of viral diseases of unknown 
etiology, and donors who have had thoracic diseases or 
thoracic trauma involving the trachea. 
Organ procurement is performed under clean but not 
sterile conditions. The trachea is removed circumferen- 
tially from the distal end of the larynx to include the first 
30 mm of both bronchi. The trachea is then placed in 
isotonic saline solution for transport o the homograft 
bank. Tracheal homograft banks now exist in London, 
United Kingdom, and in Bonn, Germany.* 
The trachea is stripped of overlying tissue and the 
trachealis muscle is removed. The remaining anterior 
cartilaginous portion of the trachea is immersed for 14 
days in 500 ml of 4% formalin in compound sodium 
lactate solution. 19-22 The trachea is then immersed for 56 
days in 500 ml of 4 gm/L thimerosal (sodium ethylmercu- 
rithiosalicylate, a Methiolate-related compound) dis- 
solved in Dulbecco phosphate-buffered saline solution. It 
*Details regarding these tracheal homograft banks may e ob-
tained from the authors. 
is then stored in acetone for a minimum of 10 days before 
its release for clinical use. All processing and final storage 
is in autoclavable and acetone-resistant Nalgene polypro- 
pylene bottles (Nalgene, a subsidiary of Sybron, Roches- 
ter, N.Y.). Five samples of the excised trachealis muscle 
undergo the same processing until the final stage in 
acetone, at which point they are used for microbiologic 
testing. They are tested for aerobic bacteria, anaerobic 
bacteria, fungi, mycobacteria, nd hypothermic microor- 
ganisms. 
Before insertion, the homograft (Fig. 1) is washed 
thoroughly in saline solution. Histologic studies have 
confirmed that all cells in the graft die and all major 
histocompatibility complex markers are lost. 19' 2o, 23 
Surgical technique. Two surgical approaches have been 
used. Eighteen patients with shorter (less than 50% of the 
trachea) and higher level tracheal stenosis had THR via a 
collar incision in the neck, with the use of a limited sternal 
split if access proved difficult. Median sternotomy was 
used eight times in six patients for THR for longer 
(greater than 50% of the trachea), more distal lesions 
(two children required a second THR: one child in whom 
the original homograft displayed persistent anterior col- 
lapse and one child in whom recurrent stenoses developed 
14.5 months after THR). Cardiopulmonary bypass was 
used in seven of eight cases of THR via median sternot- 
omy. Cardiopulmonary b pass facilitates the dissection for 
more distal lesions down to and beyond the carina, 
simplifies the requirements for intraoperative airway 
maintenance, and is particularly useful in small in- 
fants.13, 14, 22, 24-29 Three of the six patients treated with 
median sternotomy also required emergency preoperative 
ECMO when mechanical ventilation became impossible. 
Exposure of the trachea via a transverse neck incision is 
identical to standard approaches. By means of a mixture 
of sharp and blunt dissection, the trachea is exposed 
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Fig. 2. The anterior part of the trachea is removed 
leaving only the posterior tracheal wall and trachealis 
intact. The homograft is cut to size and sutured into place 
with interrupted horizontal mattress absorbable monofil- 
ament sutures. 
/ 
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Fig. 3. The stent is placed to support the homograft 
internally until reepithelialization has occurred, after 
which it is removed endoscopically usually 10 to 12 weeks 
after the operation. 
beneath the pretracheal fascia. Care is taken to avoid 
the head vessels and the pulmonary artery during 
dissection. 
Patients undergoing an approach via median sternot- 
omy are positioned supine, and the skin is prepared and 
draped to expose the neck and chest. Potential incision 
sites are marked with a surgical marker pen. A conven- 
tional median sternotomy is performed and the thymus 
excised. Before the pericardium is opened, the head 
vessels are dissected and vascular slings are passed around 
them to permit retraction. The pretracheal fascia is 
opened in the midline and the upper (normal) trachea is 
identified. 
The pericardium is then opened longitudinally and stay 
sutures are applied. The superior vena cava, the aorta, the 
pulmonary arteries, and the innominate vein are mobi- 
lized and vascular slings or tapes are passed around them 
to facilitate retraction. Heparin is given and purse-string 
sutures are inserted into the upper left aspect of the aorta 
and the right atrial appendage. A flexible, wire-wound 
aortic cannula is preferred to permit safe and repeated 
repositioning. A right-angled Rygg cannula (Polystan A/S, 
Vaerlose, Denmark) is used for venous drainage. The 
bypass is run at a temperature between 32 ° and 37 ° C and 
with a hematocrit value greater than 35%. 
The trachea is further exposed between the aorta and 
the superior vena cava. The incision in the pretracheal 
fascia is continued own to below the lower limit of the 
stenosis. A laryngeal release and bilateral hilar releases 
allow complete tracheal mobilization. Both the left and 
right main-stem bronchi can be mobilized if necessary. 
With these maneuvers, it is often possible to treat very- 
long-segment s enoses, often extending from cricoid car- 
tilage superiorly to below the carina inferiorly. 
Once cardiopulmonary b pass has been safely estab- 
lished, the anterior trachea is incised longitudinally in the 
middle of the stenosis. At this stage, one must make a 
decision as to the preferred procedure, because it is still 
possible to perform either a slide tracheoplasty or another 
conservative operation if preferred. Once one has decided 
to perform THR, then the anterior incision in the trachea 
is continued both cephalad and caudad until normal 
trachea or bronchus is reached. The lateral walls of the 
narrowed segment are then removed, leaving only the 
posterior wall in continuity (Fig. 2). 
It is often necessary to create a series of longitudinal, 
partial-thickness lits in the posterior emnant in pa- 
tients with complete tracheal rings or rigid scar tissue 
down the posterior wall of the trachea. With cardiopul- 
monary bypass, electrocautery is preferred for these 
incisions to minimize hemorrhage. The rationale for 
these slit incisions is to create partially everted margins 
in the posterior wall in settings where that component is
made of solid cartilage or complete tracheal rings. The 
everted margins reflect a splayed out posterior wall 
creating an advantageous morphology to receive the 
tracheal homograft. 
One or two temporary silicone intraluminal stents (Du- 
mon stents, Axiom, Lyon, France) (see Fig. 1) are then 
placed onto the posterior wall and sutured to the native 
trachea with 4 to 6 single absorbable monofilament su- 
tures (Fig. 3). These sutures are placed at the upper and 
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Fig. 4. Bronchoscopic examination 13 months after THR revealing a completely epithelialized homograft 
with a normal caliber airway from cricoid to carina. 
Fig. 5. Electron micrograph shows the appearance of the homograft in the first week after implantation. 
The absence of epithelium is apparent. 
lower ends of the stents to minimize movement of the 
stents. The stent(s) will provide a good support to the 
tracheal homograft, which undergoes a period of soften- 
ing in the early days after insertion. (Because oversized 
adult tracheal homo~afts are used even in small children, 
the Dumon stent should always fit. Our youngest patient 
was 5 months at the time of THR and received an 
oversized homograft, allowing easy placement of a Du- 
mon stent with a 5 mm internal luminal diameter to stent 
an obviously arger airway.) 
Before the next stage is begun, the endotracheal tube 
can be repositioned under di ect vision to lie inside the 
upper orifice of the Dumon stent. The graft is then 
trimmed to reflect the defect in the anterior trachea 
before being sutured in place with interrupted horizontal 
mattress absorbable monofilament sutures. These hori- 
zontal mattress sutures join the homograft to the posterior 
tracheal remnant. 
Intraoperative bronchoscopy is performed to confirm 
graft patency and to allow bronchial toilet. The suture line 
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Fig. 6. Eight weeks after THR, early epithelialization and budding can be seen on the surface of the 
underlying matrix. 
Fig. 7. Two months after THR, the presence of ciliated respiratory epithelium is clearly demonstrated. 
of the homograft anastomosis is sealed and made airtight 
with Tisseel fibrin glue (Immuno AG, Vienna, Austria). 
Cardiopulmonary b pass, if used, is withdrawn. Hemosta- 
sis and routine closure follow. 
Postoperative care. All patients require prolonged 
stays in the intensive care unit and benefit from a multi- 
disciplinary approach involving cardiac surgeons, intensiv- 
ists, otolaryngologists, and especially a dedicated nursing 
staff. Personnel skilled in emergency bronchoscopy must 
be readily available for treatment of acute airway prob- 
lems. Frequent postoperative treatment with a rigid bron- 
choscope is necessary to clear granulation tissue for 
several weeks as the homograft undergoes epithelializa- 
tion. Local temporary stenoses from exuberant granula- 
tion tissue may also be treated with balloon dilatation 
through the rigid bronchoscope. Postoperative antibiotic 
coverage includes 2 weeks of intravenous therapy and 4 
additional weeks of oral trimethoprim. Inhaled steroids 
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Fig. 8. Patient outcome.* Twenty-three ofthe 24 patients had had unsuccessful prior tracheal reconstruc- 
tion. 
are used to help decrease granulation tissue. Adrenaline 
nebulizers also are used. 
The intraluminal stent(s) support(s) the homograft or 
10 to 12 weeks until the homograft hardens and reepithe- 
lialization has occurred. After bronchoscopic examination 
visually confirms that the granulation tissue no longer 
exists and that the inner surface of the homograft has 
undergone r epithelialization, the stent is removed. En- 
doscopic stent removal is usually not difficult because the 
absorbable sutures previously holding the stent will have 
dissolved. The stent can be grasped, rotated medially, 
folded onto itself, and withdrawn. After discharge from 
the hospital, short-term bronchoscopic follow-up is nec- 
essary. Immunosuppression is ot used. 
Resu l ts  
Early mortality occurred in one patient (1/24 = 
4.2%) who underwent THR at 5 months of age after 
4 days of ECMO support. This child had undergone 
previous tracheoptasty at 2 months of age for long- 
segment congenital tracheal stenosis and returned 
with severe recurrent tracheal stenosis. ECMO was 
instituted as mechanical ventilation became impos- 
sible. Severe intraoperative pulmonary hemorrhage 
necessitated the continuation of ECMO in the post- 
operative period and the child died 10 days after 
THR of a catastrophic ntraabdominal hemorrhage. 
Late mortality occurred in three patients (3/24 = 
12.5%); however, only one patient (1/24 = 4.2%) 
died late with airway (tracheal) problems. This 
infant with long-segment congenital tracheal steno- 
sis had a sepsis-related anastomotic dehiscence after 
primary tracheoplasty and then had an unsuccessful 
patch revision. Subsequent mediastinitis necessi- 
tated ECMO support. This infant later underwent 
THR after 4 days of ECMO to allow for local 
control of sepsis. The airway stabilized sufficiently to 
allow separation from ECMO 3 days after THR, but 
the child died 3.5 months later of further sepsis and 
airway failure. 
Two other patients died late with functional air- 
ways. One victim of multiple trauma died of cardiac 
failure despite a completely functional airway after 
THR. A second late death occurred in a child with 
recurrent long-segment congenital tracheal stenosis 
who died 18 months after THR of unrelated gastro- 
intestinal problems despite a completely functional 
airway. 
Twenty patients urvive (20/24 = 83.3%). Sixteen 
patients are now free of symptoms and without 
airway problems. Four are still undergoing treat- 
ment. Follow-up has ranged from 5 months to 10 
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Fig. 9. Actuarial survival (Kaplan-Meier) after tracheal homograft replacement in children. G/, Gastro- 
intestinal. 
years (mean _+ SEM = 3.79 _+ 0.70 years). No 
patients required tracheostomy after tracheal ho- 
mograft reconstruction. 
The 16 children currently free of airway prob- 
lems have all demonstrated stable and functional 
tracheal homografts, with bronchoscopic exami- 
nation revealing reepithelialization of the lumen 
(Fig. 4). Histologic studies have confirmed the 
presence of ciliated respiratory epithelium (Figs. 
5 to 7). No patients have had rejection or have 
required immunosuppression. No patients have 
had homograft calcification either clinically or 
radiographically. 
Only one patient survives of the three patients 
who required preoperative ECMO. 3° At another 
institution, this 5-month-old infant had an unsuc- 
cessful attempt at balloon dilation for long-segment 
congenital tracheal stenosis and had a cardiopulmo- 
nary arrest after the procedure, requiring the initi- 
ation of ECMO. Four days later, THR was per- 
formed and ECMO was discontinued. The child was 
at home, without major airway problems, and grow- 
ing normally. 3° However, tracheal stenosis recurred 
and was treated with a second THR 14.5 months 
after the original replacement. This child has since 
been extubated. He is recovering well and awaiting 
stent removal. 
The overall patient outcome, analyzed by tracheal 
disease and surgical approach, is depicted in Fig. 8. 
Fig. 9 demonstrates actuarial survival (Kaplan- 
Meier) after THR. 
Discussion 
Tracheal homograft reconstruction represents a
novel therapeutic modality with encouraging short- 
term to medium-term results for children with se- 
vere long-segment congenital tracheal stenosis or 
recurrent racheal stenosis in whom conventional 
management has failed. Numerous techniques have 
been described for the treatment of long-segment 
congenital tracheal stenosis and recurrent racheal 
stenosis. These techniques include endobronchial 
stenting, 18 aggressive balloon dilation, 1°' 11 pericar- 
dial patch tracheoplasty, 12'13 cartilage and rib graft 
tracheoplasty, 14'1s omental pedicle flap tracheo- 
bronchial reconstruction, 16 and slide tracheoplas- 
ty.7, 9 In all series, an important subgroup of patients 
exists in whom conventional treatment fails. THR 
allows tracheal reconstruction when less of the 
patient's own tracheal tissue is available and allows 
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tracheal reconstruction when conventional treat- 
ment may be considered impossible or dangerous. 
Other options for tracheal replacement in human 
beings have not been successful. Synthetic tracheal 
prostheses have led to an intense inflammatory reac- 
tion with airway obstruction, prosthesis migration, 
and erosion of major blood vessels often leading 
to fatal hemorrhage. 8 Tracheal allografts not sub- 
jected to chemical preparation and transplanted 
in animal models are subject to immunologic 
recognition and rejection. 31' 32 Allogenic vascular- 
ized transplants with the use of immunosuppres- 
sion have been studied in dogs but have not been 
successfully applied to human beings. 33 Tracheal 
homografts, chemically prepared as described in 
this article, avoid the intense inflammatory reac- 
tion caused by synthetic tracheal prostheses and 
also avoid the need for immunosuppression. 
Thimerosal-preserved cartilage had previously 
been investigated in the laboratory. 34 Because of the 
lack of a suitable alternative, Herberhold began 
placing chemically preserved tracheal homografts 
into adults, starting in 1979. The homograft pos- 
sesses the characteristics of both avascularity and 
avitality.19, 23, 34 The chemical preparation has been 
shown to destroy the homograft's immunologic an- 
tigens. 35 Thus immunosuppression is thought not 
necessary. The chemically treated and preserved 
homograft acts as a biocompatible implant with no 
intrinsic cellular viability. It can be thought of as a 
skeleton, allowing fibroblasts to grow inward be- 
tween cartilage rings and eventually permitting epi- 
thelialization from within the lumen. Immunologic 
investigation i human beings has demonstrated the 
absence of evidence of systemic immunoactivation 
or signs of clinical rejection after THR. 23 
The success with THR in adults 19-21 led to the 
eventual pediatric application of this technique. All 
but one of the pediatric ases of THR were in the 
setting of previous failed tracheal reconstructive 
attempts. Many of these patients had had several 
unsuccessful conventional tracheal reconstructive 
procedures, uch as balloon dilatation, tracheal re- 
section and reanastomosis, and pericardial patch 
tracheoplasty, at a variety of institutions. All were 
thought o be poor candidates for further standard 
conventional procedures because of the severity of 
their tracheal disease, the degree of tracheal thick- 
ening, and the large amount of scar tissue caused by 
previous interventions. Previous tracheal proce- 
dures often resulted in poor tracheal blood supply 
and decreased tracheal mobility. Because of this 
lack of mobility and compromised tracheal blood 
supply, THR was used. The success of THR in the 
adult population along with the recurrence of ste- 
nosis after conventional techniques in these children 
made THR an appealing option. 
The tracheal homograft has numerous advantages 
including adequate availability, nearly circumferen- 
tial tissue for reconstruction, and a carina that may 
be used to permit extensive repair. In addition, the 
procedure can be repeated if required. Follow-up 
bronchoscopic and histologic studies have shown 
clear evidence of luminal epithelialization. Ciliated 
columnar espiratory epithelium has been shown to 
cover the lumen of the homograft. 19-24 Studies are 
now underway scientifically to evaluate long-term 
airway and pulmonary function. 
An important possible disadvantage of THR is 
that the growth potential of the tracheal homograft 
is not known. Although the remaining autogenous 
trachea may grow, no evidence xists to suggest that 
the tracheal homograft itself will grow. However, 
because an oversized, adult-sized homograft has 
been used in children, problems related to lack of 
homograft growth have been avoided. Of course, 
THR can be repeated if necessary. 
The role of THR in the management of tracheal 
disease is not yet established. THR certainly repre- 
sents an important additional option for the treat- 
ment of severe long-segment congenital tracheal 
stenosis or recurrent tracheal stenosis. Our current 
approach for recurrent short-segment upper tra- 
cheal stenosis is THR. For recurrent long-segment 
congenital tracheal stenosis, if nonoperative treat- 
ment fails, we attempt o use slide tracheoplasty. If 
the length of the stenosis is too long or scar forma- 
tion too severe for this option, we then would use 
some form of augmentation tracheoplasty, possibly 
with rib cartilage. We reserve THR for children in 
whom these other alternatives do not seem suitable. 
THR was used as primary surgical therapy in only 
one infant who had required emergency ECMO 
after unsuccessful balloon tracheoplasty. THR 
should currently be seen as an addition to the 
available list of therapeutic options for tracheal 
stenosis, not as a replacement for them. 
Conclusion 
THR is a novel therapeutic modality with encour- 
aging short-term to medium-term results for chil- 
dren with severe long-segment congenital tracheal 
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stenosis or recurrent tracheal stenosis. Postopera- 
tive bronchoscopic and histologic studies provide 
evidence of epithelialization and support the expec- 
tation of good long-term results. 
Illustrations were drawn by Becan Rickard-Elliott. 
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Discuss ion 
Dr. Thomas L. Spray (Philadelphia, Pa.). I would like to 
congratulate the authors on bringing to our attention 
another therapeutic modality for patients with complex 
tracheal problems. Obviously there are several ap- 
proaches to long-segment tracheal stenosis, including the 
use of more viable tissues, such as rib cartilage grafts for 
long-segment tracheal obstruction, as our group reported 
at this meeting last year. 
I would like to ask several questions about this tech- 
nique. I noted that about two thirds to three quarters of 
the patients had a cervical approach for the tracheal 
reconstruction. If you could use a cervical approach, was 
the length of trachea that was involved short enough to 
consider some other primary repair option? How many 
patients did you actually operate on and decide at the time 
of surgery that you could do a slide tracheoplasty or an 
additional resection and therefore abandon the use of the 
homograft? 
The second question concerns the size of the homograft 
that you have used for this procedure. You mentioned 
that homografts were harvested from patients from 16 to 
60 years of age, and yet you implanted them in patients as 
young as several months of age. Does the size discrepancy 
of the homograft cause any problem, especially in the 
lower portion of the trachea? How do you decide which 
size to use in any individual patient? 
I noticed that several of your patients had long-segment 
tracheal stenosis associated with pulmonary artery sling. 
One of the problems with pulmonary artery sling and 
tracheal stenosis is that there is often a tracheal bronchus 
high in the upper portion of the trachea. How do you deal 
with that at the time of tracheal homograft implantation 
and stent implantation? Is there a problem with obstruc- 
tion of the right upper lobe takeoff rom the trachea? 
Finally, I noted that all of these patients in your series 
had surgery for stenosis. Have you used this technique for 
patients who have localized or long-segment tracheoma- 
lacia? It seems that there could be wide application of this 
technique in tracheomalacia, especially in children. 
Dr. Jacobs. Thank you, Dr. Spray, for your questions. 
First, in our series it is true that the majority of the 
patients were operated on by means of a cervical ap- 
proach. Higher recurrent tracheal stenosis often involves 
a shorter segment. Therefore we can approach the lesion 
via a cervical approach and are inclined to proceed 
directly to THR. With the longer stenoses more distally, 
we more often consider other options, like rib, before 
proceeding to the THR. 
In the past 3 months we have switched to a slide 
tracheoplasty from our initially intended THR in one 
patient. Slide tracheoplasty, pericardial tracheoplasty, and 
rib tracheoplasty are techniques that we do occasionally 
use. We try to choose whichever technique we believe is 
appropriate for the given anatomy. 
Regarding the size of the homografts, it is true that the 
homografts that we use come from donors aged 16 to 60 
years. We try to insert as large a homograft as is reason- 
able so that we will have reasonable luminal augmenta- 
tion. Our homografts do not grow; consequently, we 
believe it is important o get the largest lumen that we 
think we can safely fit. 
We try to mobilize the tracheal bronchus o that it is 
actually in the area of the carina and can be attached to 
the carina of the homograft. In actuality, the last patient 
who underwent a slide tracheoplasty had a tracheal bron- 
chus. Part of the reason that we chose to use a slide 
tracheoplasty was because of that given anatomy. 
Finally, we have not yet used this technique for tracheo- 
malacia, although that is a very interesting thought. THR 
may play a role in tracheomalacia in the future. 
Dr. Hermes C. Grillo (Boston, Mass.). We should be 
cautious about applying this technique as primary treat- 
ment for cases of long-segment s enosis because there are 
methods that have proven to be increasingly successful, 
namely, patch tracheoplasties with viable tissue, both 
pericardium and the more rigid cartilage. Since you are 
essentially using a piece of tanned tissue, formalin fixed, as 
a patch, I am not sure what its advantages are over 
autogenous cartilage, which also becomes epithelialized, 
or over slide tracheoplasty, which has the value of using 
the patient's own trachea nd epithelium. 
Chemically fixed pieces of tissue are replaced by scar 
ultimately, leaving some residual tracheal widening. Epi- 
thelialization has not generally been seen over extensive 
patch replacements with dead tissue. 
A second question is, why do you need to do any release 
procedures when you do not resect any trachea? You are 
simply inserting a patch. There seems to be no reason to 
add the hazards of laryngeal release or of bilateral pleural 
entry for hilar release. I believe these are unnecessary. 
Application of this technique to posttraumatic and 
postintubation stenoses puzzles me. In posttraumatic 
strictures, most of the time there has been no loss of 
trachea, just separation, and these ends can be brought 
together quite easily, even though they appear to be 
long-segment stenoses. In postintubation patients, we 
have found that more than 95% of strictures can be 
successfully treated by direct resection and reconstruction, 
even in children, unless the trachea has been damaged by 
previous unsuccessful therapy. Of course, in circumferen- 
tial postintubation strictures the damage is full thickness 
and inserting a gusset in the front is not going to prevent 
recicatrization circumferentially. This is a contribution 
that needs to be followed, and we will look forward to 
seeing how it works out. 
Dr. Jaeobs. Thank you, Dr. Grillo, for your questions 
and comments. We agree that there are many good 
options for the treatment of primary tracheal stenosis. 
Until now, with the exception of one case, we have 
reserved THR for use in cases of recurrent racheal 
stenosis in which previous therapy has failed. 
The homograft provides several advantages over a 
patch of rib or pericardium. First, its shape allows in- 
creased luminal augmentation, and its size allows recon- 
struction over a greater length. Finally, it has a built-in 
carina. If you need to extend the reconstruction down 
beyond the carina onto one or both main-stem bronchi, it 
is somewhat easier because the homograft has a carina of 
its own. 
We use hilar and laryngeal releases to increase tracheal 
mobilization. Also, the hilar release is used only when we 
do a sternotomy approach. We use these release proce- 
dures because we are initially evaluating the trachea to see 
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if it is mobile enough after the previous operation to allow 
us to safely use another econstructive option, such as a 
slide tracheoplasty. These release procedures are just part 
of our attempted technique to evaluate for other treat- 
ment options. 
Finally, I agree completely that there are many good 
treatment options for primary posttraumatic and primary 
postintubation stenoses, including slide tracheoplasty. In
all of the cases of posttraumatic or postintubation steno- 
ses in which we have used THR, it has been in a setting of 
a recurrence with bad scar tissue. 
Thank you, Dr. Grillo and Dr. Spray, for your thought- 
ful questions and comments. I would also like to thank 
Martin Elliott for all his support and guidance. 
